MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04358913|
Recruitment Status : Recruiting
First Posted : April 24, 2020
Last Update Posted : November 5, 2021
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Device: MR scan with the Alberta linac-MR P3 system||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Device Feasibility|
|Official Title:||Northern Alberta Linac-MR Image-Guided Human Clinical Trials - 1|
|Actual Study Start Date :||August 18, 2021|
|Estimated Primary Completion Date :||August 2022|
|Estimated Study Completion Date :||August 2022|
Experimental: MR Imaging on the Alberta linac-MR P3 system
All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
Device: MR scan with the Alberta linac-MR P3 system
Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
- Number of high-quality MR image data sets acquired for each major tumour site (prostate, liver, lung, CNS, and breast) [ Time Frame: Through study completion, approximately 1 year ]Clinical radiologists, medical physicists, and radiation oncologists will work together to develop MR sequences that can delineate tumour target volumes on the Alberta linac-MR P3 system. Over the course of the trial, the clinical radiologists will work with medical physicists to optimize these sequences to allow for the development of optimal MR images, with the goal to develop of series of protocols that can be utilized to provide clear MR image guidance for each tumour group.
- Quantify the patient experience on the Linac-MR [ Time Frame: After the first and last scan, up to 5 weeks ]Participants will complete a questionnaire at the end of their first scan regarding their experience having imaging done on the Linac-MR. Participants taking part in the optional sub-study will complete the same questionnaire at the end of their last set of imaging.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04358913
|Contact: Nawaid Usmani, MD||780-432-8518||Nawaid.Usmani@ahs.ca|
|Cross Cancer Institute||Recruiting|
|Edmonton, Alberta, Canada, T6G 1Z2|
|Principal Investigator:||Nawaid Usmani, MD||Cross Cancer Institute, Alberta Health Services|